Seahawks veterans call meeting to discuss PED issue

Kam Chancellor and the Seahawks veterans called a team meeting to discuss the team's PED issue. (USATSI)
Kam Chancellor and the Seahawks veterans called a team meeting to discuss the team's PED issue. (USATSI)

On May 17, Seattle defensive end Bruce Irvin became the fifth Seattle Seahawks player since 2010 to be suspended for using performance enhancing drugs (PEDs). There have only been 50 league-wide PED suspensions in that timespan, which means the Seahawks have accounted for 10 percent of them. 

That alarming number was enough for safety Kam Chancellor and the other Seahawk veterans to call a recent team meeting to talk about the issue.

"We had our meeting. The vets put a meeting together to talk to the guys about not making the same mistakes over and over," Chancellor said, via Sirius/XM NFL radio. "You know, we gotta grow up and move past that. So that's pretty much the message right now -- growing up and not making the same mistakes over and over."

The mistakes started in December 2011 when offensive lineman John Moffitt was suspended for four games for violating the league's PED policy. Moffitt's suspension was followed in May 2012 by the suspension of fellow linemen Allen Barbre . Barbre, who sat out the first four games of the 2012 season, was cut shortly after serving his four-game suspension and now plays for the Philadelphia Eagles

Safety Winston Guy and cornerback Brandon Browner also served suspensions during the 2012 season. 

Here's a list of the teams with three or more PED suspensions since 2010 (via ESPN.com):

Five suspensions: Seahawks.

Four suspensions: Denver Broncos , New York Giants .

Three suspensions: New England Patriots , Washington Redskins , Cincinnati Bengals , Houston Texans , St. Louis Rams

CBS Sports Writer

John Breech has been at CBS Sports since July 2011 and currently spends most of his time writing about the NFL. He's believed to be one of only three people in the world who thinks that Andy Dalton will... Full Bio

Show Comments Hide Comments
Our Latest Stories